Brian P. Landry

Brian P. Landry

Auto-generated profile, based on publicly available information

Brian P. Landry

BillionToOne, Inc

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSSebastian R. Schmidl
Sebastian R. Schmidl
FEFelix Ekness
Felix Ekness
KSKatri Sofjan
Katri Sofjan
KDKristina N.-M. Daeffler
Kristina N.-M. Daeffler
KBKathryn R. Brink
Kathryn R. Brink
JTJeffrey J. Tabor
Jeffrey J. Tabor

12 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBrian P. Landry
Brian P. Landry
RPRohan Palanki
Rohan Palanki
NDNikola Dyulgyarov
Nikola Dyulgyarov
LHLucas A. Hartsough
Lucas A. Hartsough
JTJeffrey J. Tabor
Jeffrey J. Tabor
Two-component systems (TCSs) are the largest family of multi-step signal transduction pathways in biology, and a major source of sensors for biotechnology. However, the input concentrations to which biosensors respond are often mismatched with application requirements. Here, we utilize a mathematical model to show that TCS detection thresholds increase with the phosphatase activity of the sensor histidine kinase. We experimentally validate this result in engineered Bacillus subtilis nitrate and E. coli aspartate TCS sensors by tuning their detection threshold up to two orders of magnitude. We go on to apply our TCS tuning method to recently described tetrathionate and thiosulfate sensors by mutating a widely conserved residue previously shown to impact phosphatase activity. Finally, we apply TCS tuning to engineer B. subtilis to sense and report a wide range of fertilizer concentrations in soil. This work will enable the engineering of tailor-made biosensors for diverse synthetic biology applications.

2 May 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
EWErik R. Westin
Erik R. Westin
DTDavid S. Tsao
David S. Tsao
OAOguzhan Atay
Oguzhan Atay
BLBrian P. Landry
Brian P. Landry
PYPatrick P. Ye
Patrick P. Ye
VSVivien A. Sheehan
Vivien A. Sheehan

20 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
BABrian Alford
Brian Alford
BLBrian P. Landry
Brian P. Landry
SHSarah Hou
Sarah Hou
XBXavier Bower
Xavier Bower
ABAnna M. Bueno
Anna M. Bueno
KGKathryn J. Gray
Kathryn J. Gray
We developed and validated a next generation sequencing (NGS) based NIPT assay using quantitative counting template (QCT) technology to detect RhD, C, c, E, Kell, and Fy a fetal antigen genotypes in the diverse U.S. population. The assay quantifies paternally derived fetal antigen cell-free DNA molecules after calibration to fetal fraction and a reference gene. The assay correctly determined fetal antigen status for 1061 preclinical samples with an analytical sensitivity of 100% (95% CI: 99-100%) and analytical specificity of 100% (95% CI: 99-100%). The assay showed a clear separation between antigen detected and not detected for 15,939 clinical plasma samples in a general population setting, with an estimated clinical sensitivity of 99.6%-100%. The precision of the assay in which two replicate plasma samples were independently analyzed was 99.9% for 1683 clinical samples. Moreover, a fetal antigen determination could be made for samples with RHDΨ , a variant more common among RhD-negative Black individuals. The NIPT results were 100% concordant with neonatal antigen genotype/serology for 23 RhD negative pregnant individuals and 12 other antigen evaluations in 4 alloimmunized pregnant individuals. This NGS-based fetal antigen NIPT assay had excellent performance in a validation study of samples from a diverse U.S. population for fetal fractions as low as 1.1% and as early as 10 weeks of gestation, without the need for a sample from the biological partner. Implementation of NIPT for the detection of fetal antigen in RhD-negative and alloimmunized pregnant individuals will streamline care and reduce unnecessary treatment, monitoring and patient anxiety.